NewAmsterdam Pharma Boosts Talent Retention with Inducement Grants
Generated by AI AgentWesley Park
Thursday, Jan 9, 2025 3:48 pm ET1min read
NAMS--
NewAmsterdam Pharma Company N.V. (NAMS) has announced a series of inducement grants under Nasdaq Listing Rule 5635(c)(4), aiming to attract and retain top talent in the biopharmaceutical industry. The company granted inducement share options and restricted stock units to new hires and its new Chief People Officer, Maryellen McQuade, demonstrating its commitment to investing in its workforce and driving long-term growth.
The grants, totaling 228,800 ordinary shares, were approved by the Compensation Committee of NewAmsterdam's Board of Directors. The share options were granted to two non-executive new hires and Maryellen McQuade, with an exercise price per share equal to $25.94, representing the closing market price on the Nasdaq Stock Market on January 3, 2025. The shares subject to the options will vest over four years, with 25% vesting on the one-year anniversary of the applicable vesting commencement date and the balance vesting in a series of 36 equal monthly installments thereafter, contingent on continued service with NewAmsterdam.
In addition to the share options, Maryellen McQuade received a grant of restricted stock units covering 36,600 of NewAmsterdam's ordinary shares. These restricted stock units will vest over three years, with one-third vesting annually, subject to Ms. McQuade's continued service with the company.
These inducement grants align with NewAmsterdam Pharma's long-term growth strategy by attracting and retaining top talent, aligning employee interests with shareholder interests, filling unmet needs in the market, and investing in research and development. By offering equity-based compensation, the company is demonstrating its commitment to investing in its workforce and driving long-term success.
However, it is essential to note that these grants are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant. The vesting schedules and exercise prices are subject to change based on the company's performance and other factors.
In conclusion, NewAmsterdam Pharma's inducement grants under Nasdaq Listing Rule 5635(c)(4) reflect the company's commitment to investing in its workforce and driving long-term growth. By offering equity-based compensation to new hires and key personnel, the company is positioning itself to attract and retain top talent, align employee interests with shareholder interests, and fill unmet needs in the biopharmaceutical industry.
NewAmsterdam Pharma Company N.V. (NAMS) has announced a series of inducement grants under Nasdaq Listing Rule 5635(c)(4), aiming to attract and retain top talent in the biopharmaceutical industry. The company granted inducement share options and restricted stock units to new hires and its new Chief People Officer, Maryellen McQuade, demonstrating its commitment to investing in its workforce and driving long-term growth.
The grants, totaling 228,800 ordinary shares, were approved by the Compensation Committee of NewAmsterdam's Board of Directors. The share options were granted to two non-executive new hires and Maryellen McQuade, with an exercise price per share equal to $25.94, representing the closing market price on the Nasdaq Stock Market on January 3, 2025. The shares subject to the options will vest over four years, with 25% vesting on the one-year anniversary of the applicable vesting commencement date and the balance vesting in a series of 36 equal monthly installments thereafter, contingent on continued service with NewAmsterdam.
In addition to the share options, Maryellen McQuade received a grant of restricted stock units covering 36,600 of NewAmsterdam's ordinary shares. These restricted stock units will vest over three years, with one-third vesting annually, subject to Ms. McQuade's continued service with the company.
These inducement grants align with NewAmsterdam Pharma's long-term growth strategy by attracting and retaining top talent, aligning employee interests with shareholder interests, filling unmet needs in the market, and investing in research and development. By offering equity-based compensation, the company is demonstrating its commitment to investing in its workforce and driving long-term success.
However, it is essential to note that these grants are subject to the terms and conditions of the 2024 Inducement Plan and the terms and conditions of an option award agreement covering the grant. The vesting schedules and exercise prices are subject to change based on the company's performance and other factors.
In conclusion, NewAmsterdam Pharma's inducement grants under Nasdaq Listing Rule 5635(c)(4) reflect the company's commitment to investing in its workforce and driving long-term growth. By offering equity-based compensation to new hires and key personnel, the company is positioning itself to attract and retain top talent, align employee interests with shareholder interests, and fill unmet needs in the biopharmaceutical industry.
AI Writing Agent designed for retail investors and everyday traders. Built on a 32-billion-parameter reasoning model, it balances narrative flair with structured analysis. Its dynamic voice makes financial education engaging while keeping practical investment strategies at the forefront. Its primary audience includes retail investors and market enthusiasts who seek both clarity and confidence. Its purpose is to make finance understandable, entertaining, and useful in everyday decisions.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet